Picture of Amplia Therapeutics logo

ATX — Amplia Therapeutics News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Australia's Amplia Therapeutics gains after patent grant in Europe, Japan

** Shares of Australia's Amplia Therapeutics  ATX.AX  rise
as much as 7.4% to A$0.145, on track to record their second
consecutive day of gains, if trend holds
    ** The drug developer says it has been granted a key patent
in Europe and Japan
    ** Patent for a chemical form of co's FAK inhibitor
Narmafotinib
    ** Narmafotinib is the inhibitor of the protein FAK, a
protein overexpressed in pancreatic and other cancers, drug
target gaining increasing attention for its role in solid
tumours - ATX
    ** Nearly 1.1 mln shares change hands, vs 30-day average
volume of 765,686 shares
    ** Stock up 73.6% YTD, as of last close

    

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com))

Recent news on Amplia Therapeutics

See all news